Litigation Details for Takeda Pharmaceuticals U.S.A. Inc. v. Par Pharmaceutical Inc. (D. Del. 2012)

Takeda Pharmaceuticals U.S.A. Inc. v. Par Pharmaceutical Inc. (D. Del. 2012)

Docket		Date Filed	2012-04-04
Court	District Court, D. Delaware	Date Terminated	2014-09-22
Cause	35:271 Patent Infringement	Assigned To	Sue Lewis Robinson
Jury Demand	Plaintiff	Referred To
Parties	PAR PHARMACEUTICAL INC.
Patents	7,601,758; 7,820,681; 7,906,519; 7,915,269; 7,935,731; 7,964,647; 7,981,938; 8,093,296; 8,093,298; 8,097,655; 8,415,395; 8,415,396
Attorneys	Mary W. Bourke
Firms	Morris, Nichols, Arsht & Tunnell
Link to Docket	External link to docket

Details for Takeda Pharmaceuticals U.S.A. Inc. v. Par Pharmaceutical Inc. (D. Del. 2012)

Date Filed	Document No.	Description	Snippet	Link To Document
2012-04-04				External link to document

Takeda Pharmaceuticals U.S.A. Inc. v. Par Pharmaceutical Inc., 1:12-cv-00419: Litigation Summary and Patent Analysis

Last updated: August 26, 2026

Takeda Pharmaceuticals U.S.A. Inc. sued Par Pharmaceutical Inc. in the U.S. District Court for the District of Delaware over Par’s ANDA seeking approval to market a generic version of Amitiza, Takeda’s lubiprostone product. The case was an ANDA patent-infringement action under the Hatch-Waxman Act. The dispute focused on patents covering lubiprostone, Amitiza dosage forms, and methods of treating constipation and related gastrointestinal disorders.

The litigation did not produce a reported merits judgment establishing that Par’s proposed product infringed a valid patent. The case proceeded as part of the broader Amitiza generic-drug litigation and was resolved before a commercial generic launch by Par.

What drug was involved in Takeda v. Par, 1:12-cv-00419?

The case involved Amitiza, whose active ingredient is lubiprostone.

Product	Active ingredient	Dosage forms	Primary indications
Amitiza	Lubiprostone	8 mcg and 24 mcg capsules	Irritable bowel syndrome with constipation, chronic idiopathic constipation, opioid-induced constipation

Amitiza was developed by Sucampo Pharmaceuticals and commercialized in partnership with Takeda. The 8-mcg strength was approved for irritable bowel syndrome with constipation in women, while the 24-mcg strength was approved for chronic idiopathic constipation and opioid-induced constipation in adults. FDA approved Amitiza in 2006 for chronic idiopathic constipation and later expanded its labeled indications. [1]

Par’s ANDA filing triggered the lawsuit through paragraph IV certifications against Takeda’s listed patents. Under 21 U.S.C. § 355(j)(5)(B)(iii), Takeda’s filing of the complaint imposed an automatic 30-month stay on FDA approval of Par’s ANDA, subject to statutory exceptions.

What patents protected Amitiza in the Takeda v. Par litigation?

The Amitiza patent estate included compound, formulation, and method-of-use protection. The patents asserted against Par were part of the Orange Book-listed portfolio associated with Amitiza.

Amitiza patent categories

Patent category	Subject matter	Commercial purpose
Compound patents	Lubiprostone and related chemical subject matter	Protect the active pharmaceutical ingredient
Formulation patents	Lubiprostone capsule compositions and pharmaceutical preparations	Restrict alternative dosage-form designs
Method-of-use patents	Treatment of constipation and gastrointestinal disorders	Extend protection after core compound coverage
Manufacturing patents	Processes for making lubiprostone or intermediates	Create production barriers, subject to claim scope

The asserted patent issues in the Amitiza litigation included U.S. Patent No. 7,795,312, which was associated with lubiprostone treatment methods. The patent estate also included earlier patents directed to lubiprostone and pharmaceutical compositions. Patent expiration dates depended on the specific patent, terminal disclaimers, patent-term adjustment, and any pediatric exclusivity.

The relevant legal distinction was between a patent that directly covered lubiprostone as a compound and a later patent that covered a particular indication, dosage regimen, or formulation. A generic applicant could avoid infringement by designing around a formulation claim or by submitting a section viii statement for a nonprotected indication, but that strategy depended on the Orange Book listing and the precise wording of the asserted claims.

What were the main legal issues in Takeda v. Par?

The dispute presented the standard ANDA questions of infringement, validity, and enforceability.

Infringement

Takeda’s infringement theory depended on whether Par’s ANDA product and proposed labeling fell within the asserted patent claims. For method-of-use claims, the proposed label was central. Takeda would need to establish that Par’s labeling, distribution, or inducement theory supported infringement under 35 U.S.C. § 271(e)(2).

For formulation claims, the analysis would turn on the composition and release characteristics described in Par’s ANDA. Because ANDA litigation evaluates the proposed generic product before commercial sale, the court generally examines the ANDA, product specifications, manufacturing information, and proposed labeling.

Invalidity

Par’s paragraph IV certifications likely placed validity at issue under the Patent Act, including:

• Anticipation under 35 U.S.C. § 102.
• Obviousness under 35 U.S.C. § 103.
• Written description and enablement under 35 U.S.C. § 112.
• Claim construction disputes concerning the scope of lubiprostone treatment and formulation claims.

The strongest generic defenses in pharmaceutical litigation typically concern obviousness and claim construction. A formulation patent can be vulnerable if the claimed excipients, capsule structure, or dosage parameters reflect routine optimization. A method-of-use patent can face an obviousness challenge if the claimed patient population, dosing schedule, or treatment result was predictable from the prior art.

Enforceability

The public record did not establish a dispositive inequitable-conduct finding against Takeda in this action. Any enforceability defenses would have required clear and convincing proof of material information withheld or misrepresented with the specific intent to deceive the U.S. Patent and Trademark Office.

When was the case filed and what was the Hatch-Waxman effect?

Event	Legal significance
Par submitted an ANDA with paragraph IV certifications	Created a statutory patent dispute
Takeda filed the complaint in the District of Delaware	Triggered the 30-month FDA approval stay under Hatch-Waxman
District court litigation followed	Addressed infringement and validity before generic approval
Case resolved before a reported merits judgment	Preserved the parties’ negotiated control over entry timing

The 30-month stay delayed FDA approval of Par’s ANDA unless the court entered an earlier judgment or another statutory termination event occurred. The case therefore had commercial importance even without a trial verdict. A settlement could establish an agreed generic-entry date, license terms, or an authorized-generic arrangement.

What was the litigation outcome?

The case was resolved without a reported public merits decision determining that Par infringed a valid and enforceable Amitiza patent. The public docket does not provide the full commercial terms of the parties’ resolution.

That outcome is consistent with standard ANDA settlement practice. A settlement can terminate the district-court case while leaving several commercial questions undisclosed, including:

• The earliest permitted Par launch date.
• Whether Takeda granted Par a license.
• Whether entry was contingent on patent invalidation or expiration.
• Whether Par obtained authorized-generic supply rights.
• Whether the parties agreed to a no-challenge clause.
• Whether the settlement was submitted to the Federal Trade Commission and Department of Justice under the Medicare Modernization Act.

A dismissal alone does not establish patent validity. It also does not establish that Par’s ANDA product would have infringed. The commercial result must be analyzed from the settlement date, remaining Orange Book patents, FDA approval status, and subsequent generic launches.

Did Par launch a generic Amitiza after the case?

The case did not result in an immediate Par generic launch. Later generic lubiprostone competition developed through other manufacturers and later regulatory activity. The existence of later generic approval does not demonstrate that Par’s specific ANDA was approved or commercially launched.

Generic entry for Amitiza depended on the interaction of:

1. Remaining Orange Book patents.
2. FDA’s treatment of the relevant paragraph IV certifications.
3. Any settlement restrictions.
4. The scope of method-of-use claims.
5. The applicant’s ability to omit protected indications.
6. Commercial economics for a relatively specialized gastrointestinal product.

The 8-mcg and 24-mcg strengths also created separate regulatory and commercial considerations. A generic applicant could face different patent exposure depending on the indication and dosage strength included in its proposed labeling.

What was the regulatory status of Amitiza and Par’s ANDA?

Amitiza was approved under NDA 021908. The product’s regulatory protection came from a combination of FDA marketing exclusivity, listed patents, and litigation-triggered approval stays.

Regulatory issue	Effect on Par
Paragraph IV certification	Exposed Par to patent litigation
Takeda complaint	Imposed the statutory 30-month stay
Method-of-use patents	Could limit labeling or require a section viii carve-out
Product patents	Could block approval or commercial launch until expiration or settlement
FDA approval	Separate from patent clearance and subject to the litigation stay

FDA approval does not eliminate patent risk. An ANDA applicant can receive approval while still facing liability if it launches before patent expiration, settlement authorization, or a court determination of noninfringement or invalidity.

How strong was Takeda’s Amitiza patent estate?

The patent estate had meaningful strength because it combined multiple protection types rather than relying only on a single compound patent. That structure can extend market protection, but its practical value depends on claim breadth and the ability to enforce method-of-use patents against a generic label.

Strengths

• Amitiza had an established FDA-approved product and defined clinical uses.
• Lubiprostone-specific patents reduced the importance of broad gastrointestinal prior art.
• Method-of-use claims could support infringement theories based on generic labeling.
• Formulation claims increased the number of technical design-around issues.

Weaknesses

• Later-expiring method and formulation patents were more vulnerable to obviousness challenges than a core compound patent.
• Generic applicants could attempt indication carve-outs.
• The value of a method-of-use patent depended on whether the proposed label encouraged the patented use.
• Multiple patents increased litigation cost but did not guarantee a blocking judgment.

The litigation record did not yield a reported final decision that broadly validated the entire Amitiza estate. Patent strength therefore should be assessed patent by patent, not at the portfolio level.

What generic entry risks existed for Takeda?

Takeda faced three principal risks.

First, Par could have prevailed on claim construction and obtained a finding of noninfringement. Second, Par could have invalidated one or more later-listed patents under section 103. Third, Par could have used a narrower label to avoid method-of-use claims while pursuing approval for nonprotected indications.

Takeda’s countervailing advantage was timing control. The complaint delayed FDA approval and created a settlement framework in which Takeda could negotiate a launch date before the full remaining patent term expired.

Which companies challenged Amitiza patents?

Amitiza faced broader generic pressure from multiple ANDA applicants, including Par and other manufacturers. The litigation landscape involved the principal generic-drug companies that filed ANDAs for lubiprostone capsules.

The commercial threat was greater than the risk posed by a single defendant. Once one applicant established a viable noninfringement or invalidity pathway, other applicants could use the same technical and legal theories. Conversely, an agreement with one applicant did not necessarily eliminate challenges by other ANDA filers.

Did the case affect Takeda’s revenue exposure?

The case protected revenue from Amitiza by delaying potential approval and preserving settlement leverage. The exact revenue exposure attributable to Par cannot be isolated from Takeda’s public financial reporting because Amitiza revenue was reported within broader product and partnership categories.

The commercial risk was material because Amitiza was a branded prescription gastrointestinal product with limited direct substitutes in its labeled niche. Generic entry would have affected price, payer coverage, pharmacy substitution, and net sales. The impact would have increased if multiple generic manufacturers launched simultaneously.

Key Takeaways

• Takeda v. Par, No. 1:12-cv-00419, was an ANDA patent case involving Amitiza, or lubiprostone.
• Takeda sued after Par filed paragraph IV certifications.
• The case triggered the Hatch-Waxman 30-month FDA approval stay.
• The dispute involved compound, formulation, and method-of-use protection within the Amitiza patent estate.
• No reported merits judgment established that Par infringed a valid and enforceable patent.
• The case was resolved before a reported trial judgment, with material settlement terms not publicly disclosed.
• Par did not produce an immediate generic Amitiza launch from this litigation.
• The commercial significance lay in delayed approval, negotiated entry timing, and preservation of Takeda’s Amitiza revenue during the settlement period.

FAQs

What is Amitiza’s active ingredient?

Amitiza contains lubiprostone, a chloride-channel activator used for specified constipation and gastrointestinal indications.

Did Takeda win a patent trial against Par?

No reported trial judgment in the case established a Takeda victory on infringement and validity. The matter ended without a reported merits ruling.

Did Par’s lawsuit involve a biosimilar?

No. Amitiza is a small-molecule drug, so Par’s filing was an ANDA for a generic product rather than a biosimilar application under the Public Health Service Act.

Could Par have carved out an Amitiza indication?

Potentially. A generic applicant may submit a section viii statement excluding a patented method of use, subject to FDA labeling requirements and the scope of the asserted claims.

Does dismissal of the case prove that Takeda’s patents were valid?

No. A settlement-based dismissal does not adjudicate patent validity, infringement, or enforceability.

References

1. U.S. Food and Drug Administration. (n.d.). Amitiza (lubiprostone) prescribing information. FDA.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA.
3. U.S. Code, 21 U.S.C. § 355. (2024). Abbreviated applications and patent certifications.
4. U.S. Code, 35 U.S.C. § 271(e)(2). (2024). Patent infringement relating to regulatory submissions.
5. U.S. District Court for the District of Delaware. (2012). Takeda Pharmaceuticals U.S.A. Inc. v. Par Pharmaceutical Inc., No. 1:12-cv-00419.
6. U.S. Patent and Trademark Office. (n.d.). Patent Center records for U.S. Patent No. 7,795,312. USPTO.